Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.

Abstract

Clinical trials have validated the importance of mammalian target of rapamycin (mTOR) as a targeted mechanism in the treatment of renal cell carcinoma (RCC). Temsirolimus, an mTOR inhibitor that is approved for treatment of advanced RCC, has demonstrated both overall survival benefits and progression-free survival benefits versus interferon-alpha as first-line treatment for patients with poor prognostic features. Exploratory subset analyses indicated that temsirolimus benefits patients with RCC regardless of tumor histology or nephrectomy status. Everolimus, the second mTOR inhibitor to demonstrate activity in RCC, improved progression-free survival versus placebo in patients whose disease progressed after treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors (sunitinib, sorafenib, or both); benefit was observed for all risk groups. Deforolimus also exhibited antitumor activity against RCC in early clinical studies. There is now compelling clinical evidence for the effectiveness of targeting mTOR in the treatment of RCC.

• Authors: Anil Kapoor, Robert A Figlin
• Journal: Cancer (Cancer) Vol. 115 Issue 16 Pg. 3618-30 (Aug 15 2009) ISSN: 0008-543X [Print] United States
• PMID: 19479976 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• temsirolimus
• Everolimus
• Protein Kinases
• MTOR protein, human
• TOR Serine-Threonine Kinases
• Sirolimus

Topics

• Antineoplastic Agents (therapeutic use)
• Carcinoma, Renal Cell (drug therapy)
• Clinical Trials as Topic
• Drug Delivery Systems
• Everolimus
• Humans
• Kidney Neoplasms (drug therapy)
• Models, Biological
• Protein Kinases (drug effects, physiology)
• Sirolimus (analogs & derivatives, therapeutic use)
• TOR Serine-Threonine Kinases